Related Experiment Video
Updated: Feb 18, 2026
A Melanoma Patient-Derived Xenograft Model
Published on: May 20, 2019
Anorectal Melanoma: A Case Report and an Update of a Rare Malignancy
Waqas Jehangir1, Nicole Schlacter2, Shilpi Singh1
1Raritan Bay Medical Center, Perth Amboy, NJ 08861, USA.
Abstract:
Anal melanoma is an aggressive but rare malignancy. Patients commonly present with very advanced or even metastatic disease. Risk factors for anal melanoma are family history and an activating mutation of C-KIT. Surgical excision remains the mainstay of therapy. The presence of activating mutations of C-KIT has prompted use of C-KIT inhibitors such as imatinib and sunitini. Early diagnosis and treatment remain crucial. Abdominal perineal resection (APR) offers a higher rate of local control whereas wide local excision (WLE) can yield superior long-term survival.
Insights
Anal melanoma, a rare cancer, is often diagnosed at advanced stages. Treatment involves surgery and targeted therapies like imatinib, with early detection being key for better outcomes.
Area of Science:
- Oncology
- Surgical Oncology
- Medical Genetics
Background:
- Anal melanoma is a rare and aggressive malignancy.
- Patients frequently present with advanced or metastatic disease.
- Key risk factors include family history and C-KIT mutations.
Observation:
- Surgical excision is the primary treatment modality.
- C-KIT inhibitors (e.g., imatinib, sunitinib) are utilized due to C-KIT mutations.
- Abdominal perineal resection (APR) improves local control.
- Wide local excision (WLE) may offer better long-term survival.
Findings:
- Activating C-KIT mutations guide targeted therapy selection.
- Surgical approach (APR vs. WLE) impacts local control and survival.
- Early diagnosis and prompt treatment are critical for managing anal melanoma.
Implications:
- Targeted therapies show promise for C-KIT-mutated anal melanoma.
- Optimizing surgical strategy is essential for patient outcomes.
- Further research into early detection methods is warranted.
